Skip to Main Content

Paper Details

Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers.
Mol Cancer Ther
1
2023
Author NameAffiliation
Dennis J SlamonDavid Geffen School of Medicine at university of california los angeles
  • 1 - 1

Datasets

Release 1.2